Published in Tuberc Respir Dis (Seoul) on September 30, 2013
Rare etiological causes of iliofemoral deep venous thrombosis: Reports of 2 cases. Turk J Emerg Med (2016) 0.77
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J (2008) 12.31
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med (1998) 9.43
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Multidetector computed tomography for acute pulmonary embolism. N Engl J Med (2006) 7.57
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
The long-term clinical course of acute deep venous thrombosis. Ann Intern Med (1996) 6.87
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med (2006) 6.62
Acute pulmonary embolism. N Engl J Med (2010) 6.27
Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation (2005) 5.38
Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation (2011) 5.16
Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost (2007) 4.09
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59
The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol (2008) 3.50
The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med (1997) 3.49
Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol (2009) 2.79
Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med (2000) 2.77
Diagnosis and management of pulmonary embolism. BMJ (2013) 2.61
Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med (2008) 2.51
Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost (2010) 2.43
Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. BMJ (2012) 2.38
Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost (2011) 2.14
Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II Investigators. Radiology (2007) 2.09
Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation (2010) 2.05
Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med (2011) 1.98
Antithrombotic therapy for venous thromboembolic disease. Chest (2001) 1.94
Guidelines on oral anticoagulation: third edition. Br J Haematol (1998) 1.80
Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost (2006) 1.69
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost (2010) 1.39
Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res (2010) 1.18
Pulmonary embolism: prospective comparison of spiral CT with ventilation-perfusion scintigraphy. Radiology (1997) 1.17
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther (2010) 1.14
Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost (2012) 1.11
Clinical presentation of acute pulmonary embolism: survey of 800 cases. PLoS One (2012) 1.04
Origin and natural history of deep vein thrombosis of the legs. Semin Vasc Med (2005) 0.93
Advances in the diagnosis of venous thromboembolism. J Thromb Thrombolysis (2006) 0.93
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev (2011) 0.89
Venous thromboembolism. Scope of the problem. Chest (1986) 0.84
Assessment of deep vein thrombosis or pulmonary embolism by the combined use of clinical model and noninvasive diagnostic tests. Semin Thromb Hemost (2000) 0.83
Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study. Eur J Haematol (2012) 0.83
Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Thromb J (2011) 0.80
A pilot study of computed tomography-detected asymptomatic pulmonary filling defects after hip and knee arthroplasties. J Arthroplasty (2011) 0.80
Physiology of hemostasis. Clin Lab Med (1994) 0.79
Optimal duration of anticoagulant therapy. Semin Thromb Hemost (2013) 0.76
Venous thromboembolic events in the rehabilitation setting. PM R (2010) 0.76
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet (2006) 3.25
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 2.50
Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology (2014) 2.12
Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med (2013) 2.09
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood (2010) 1.89
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med (2007) 1.63
Periprocedural Management of Direct Oral Anticoagulants: Comment on the 2015 American Society of Regional Anesthesia and Pain Medicine Guidelines. Reg Anesth Pain Med (2016) 1.60
Is the network meta-analysis (NETMA) bringing us closer to the truth? Insights from recent antithrombotic drug data. Thromb Haemost (2012) 1.37
Cervical artery dissection: pathology, epidemiology and management. Thromb Res (2009) 1.33
Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke (2010) 1.19
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. Am J Hematol (2009) 1.11
Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.11
Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res (2011) 1.03
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood (2010) 0.97
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes (2010) 0.96
Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost (2008) 0.93
Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. Can J Cardiol (2013) 0.92
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther (2005) 0.92
Platelet-leukocyte aggregation under shear stress: differential involvement of selectins and integrins. Thromb Haemost (2003) 0.89
Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. Pacing Clin Electrophysiol (2009) 0.87
Thrombosis is associated with inferior survival in multiple myeloma. Haematologica (2012) 0.86
Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol (2013) 0.84
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. Thromb Haemost (2012) 0.81
Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagul Fibrinolysis (2007) 0.81
Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. Thromb Haemost (2012) 0.81
Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study. Thromb Haemost (2010) 0.81
Acquired hemophilia masked by warfarin therapy: report on two cases. Blood Coagul Fibrinolysis (2003) 0.80
Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance. Semin Hematol (2011) 0.80
Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. J Thromb Thrombolysis (2014) 0.80
Limited protective effect of the CCR5Delta32/CCR5Delta32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus. J Infect Dis (2003) 0.80
Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost (2016) 0.80
Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report. J Thromb Thrombolysis (2015) 0.80
High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. Thromb Haemost (2013) 0.79
Accuracy and safety of (99m)Tc-labeled anti-D-dimer (DI-80B3) Fab' fragments (ThromboView®) in the diagnosis of deep vein thrombosis: a phase II study. Thromb Res (2012) 0.79
A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery. Thromb Haemost (2010) 0.79
Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. Thromb Haemost (2013) 0.78
Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects. Curr Med Res Opin (2006) 0.78
Anticoagulation control with daily low-dose vitamin k to reduce clinically adverse outcomes and international normalized ratio variability: a systematic review and meta-analysis. Pharmacotherapy (2013) 0.77
Optimal reversal of vitamin K antagonists. Thromb Res (2005) 0.77
Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. Thromb Haemost (2005) 0.77
Bile acids and coagulation factors: paradoxical association in children with chronic liver disease. Eur J Gastroenterol Hepatol (2013) 0.77
Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation: a meta-analysis? Blood Coagul Fibrinolysis (2012) 0.77
NXY-059 does not affect bleeding time in healthy volunteers: a randomized, double-blind, placebo-controlled, 3-period crossover phase I study. J Clin Pharmacol (2007) 0.76
Recombinant FVIIa in children with liver disease. Thromb Res (2005) 0.76
Extended anticoagulation in venous thromboembolism. N Engl J Med (2013) 0.76
Variability of clinical manifestation of factor VII-deficiency in homozygous and heterozygous subjects of the European F7 gene mutation A294V. Haematologica (2008) 0.76
Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugs. Semin Thromb Hemost (2009) 0.76
Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol (2014) 0.76
The onerous task of comparing treatments in inhibitor patients. Thromb Haemost (2007) 0.75
Response to Dr Junqueira. Chest (2013) 0.75
Reply to Dr Lessire et al. Reg Anesth Pain Med (2016) 0.75
Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. Thromb Haemost (2015) 0.75
Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation. J Popul Ther Clin Pharmacol (2013) 0.75
Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. Br J Haematol (2006) 0.75
Determinants of Nicotine Dependence in Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis (Seoul) (2017) 0.75
Experiences of a low-intensity anticoagulation regimen for extended secondary prevention of venous thromboembolism. Hematol J (2002) 0.75
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost (2016) 0.75
The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. A randomised trial. Thromb Haemost (2016) 0.75
Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis. Thromb Haemost (2016) 0.75
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Pooled analysis of RE-COVER and RE-COVER II. Thromb Haemost (2017) 0.75
Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thromb Haemost (2016) 0.75
A step change in oral anticoagulation: lack of coagulation monitoring with ximelagatran. Semin Vasc Med (2005) 0.75